grantor: University of TorontoPrevious studies have demonstrated large age-based variations in the treatment of localized prostate cancer but have not adequately adjusted for comorbidity. This thesis investigated the role of age and comorbidity in the treatment decision. An age-stratified random sample of patients was identified from the Ontario Cancer Registry. Tumour, comorbidity, and treatment information was collected through chart review of 347 patients. Radical prostatectomy was provided to 58.7%, 32.1%, 2.6%, and 0% of patients of ages <60, 60-69, 70-79, and 80+, respectively. For radiotherapy the results were 6.4%, 30.9%, 23.4%, and 3.3%, respectively. Age had a much stronger influence on treatment than comorbidity, even w...
ObjectiveTo analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer...
PURPOSE: We sought to identify facility level variation in the use of definitive therapy among men d...
Purpose: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate ...
grantor: University of TorontoPrevious studies have demonstrated large age-based variation...
Objective To assess, in a meta-analysis of published studies, whether age influences the behaviour ...
Contains fulltext : 203364.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
PURPOSE: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either canc...
BackgroundMen aged >65 yr are less likely to receive local therapy for prostate cancer (PCa), per...
Objective: It is controversial whether age is associated with higher grade and worse out-come. Some ...
OBJECTIVE: It is controversial whether age is associated with higher grade and worse outcome. Some s...
It is acknowledged that prostate cancer occurs predominantly in elderly patients, with peak incidenc...
TO THE EDITOR: The population-based cohort in the article by Daskivich and colleagues (1) does not n...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
It’s the most common cancer among men. Prostate cancer will affect one in five men at some point in ...
ObjectiveTo analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer...
PURPOSE: We sought to identify facility level variation in the use of definitive therapy among men d...
Purpose: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate ...
grantor: University of TorontoPrevious studies have demonstrated large age-based variation...
Objective To assess, in a meta-analysis of published studies, whether age influences the behaviour ...
Contains fulltext : 203364.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
PURPOSE: To investigate the prognostic impact of the Charlson comorbidity index (CCI) on either canc...
BackgroundMen aged >65 yr are less likely to receive local therapy for prostate cancer (PCa), per...
Objective: It is controversial whether age is associated with higher grade and worse out-come. Some ...
OBJECTIVE: It is controversial whether age is associated with higher grade and worse outcome. Some s...
It is acknowledged that prostate cancer occurs predominantly in elderly patients, with peak incidenc...
TO THE EDITOR: The population-based cohort in the article by Daskivich and colleagues (1) does not n...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
It’s the most common cancer among men. Prostate cancer will affect one in five men at some point in ...
ObjectiveTo analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer...
PURPOSE: We sought to identify facility level variation in the use of definitive therapy among men d...
Purpose: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate ...